175 related articles for article (PubMed ID: 28585885)
21. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
[TBL] [Abstract][Full Text] [Related]
22. Identifying recurrent breast cancer patients in national health registries using machine learning.
Lauritzen AD; Berg T; Jensen MB; Lillholm M; Knoop A
Acta Oncol; 2023 Apr; 62(4):350-357. PubMed ID: 37074036
[TBL] [Abstract][Full Text] [Related]
23. Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer.
Lee ES; Han W; Kim MK; Kim J; Yoo TK; Lee MH; Lee KH; Kim TY; Moon HG; Im SA; Noh DY; Lee ES
BMC Cancer; 2016 Jul; 16():430. PubMed ID: 27388210
[TBL] [Abstract][Full Text] [Related]
24. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.
Overgaard M; Jensen MB; Overgaard J; Hansen PS; Rose C; Andersson M; Kamby C; Kjaer M; Gadeberg CC; Rasmussen BB; Blichert-Toft M; Mouridsen HT
Lancet; 1999 May; 353(9165):1641-8. PubMed ID: 10335782
[TBL] [Abstract][Full Text] [Related]
25. Oestrogen and progesterone receptor determinations in breast cancer: technology and biology.
Thorpe SM; Rose C
Cancer Surv; 1986; 5(3):505-25. PubMed ID: 3555780
[TBL] [Abstract][Full Text] [Related]
26. Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials.
Jensen MB; Nielsen TO; Knoop AS; Laenkholm AV; Balslev E; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):135-140. PubMed ID: 29168407
[TBL] [Abstract][Full Text] [Related]
27. Improvement of prognosis in breast cancer in Denmark 1977-2006, based on the nationwide reporting to the DBCG Registry.
Mouridsen HT; Bjerre KD; Christiansen P; Jensen MB; Møller S
Acta Oncol; 2008; 47(4):525-36. PubMed ID: 18465318
[TBL] [Abstract][Full Text] [Related]
28. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.
Ahern TP; Cronin-Fenton DP; Lash TL; Sørensen HT; Ording AG; Hamilton-Dutoit SJ; Hellberg Y
Acta Oncol; 2016 Jun; 55(6):734-41. PubMed ID: 27056567
[TBL] [Abstract][Full Text] [Related]
29. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
30. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
[TBL] [Abstract][Full Text] [Related]
31. Is conservative surgery a good option for patients with "triple negative" breast cancer?
Martinez-Ramos D; Escrig-Sos J; Torrella-Ramos A; Alcalde-Sanchez M; Salvador-Sanchis JL
Breast; 2012 Jun; 21(3):401-5. PubMed ID: 22579462
[TBL] [Abstract][Full Text] [Related]
32. Socioeconomic position and prognosis in premenopausal breast cancer: a population-based cohort study in Denmark.
Hjorth CF; Damkier P; Ejlertsen B; Lash T; Sørensen HT; Cronin-Fenton D
BMC Med; 2021 Sep; 19(1):235. PubMed ID: 34587961
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG).
Skriver SK; Laenkholm AV; Rasmussen BB; Handler J; Grundtmann B; Tvedskov TF; Christiansen P; Knoop AS; Jensen MB; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):31-37. PubMed ID: 29168427
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors for survival after first recurrence in breast cancer: a retrospective analysis of 252 recurrent cases at a single institution.
Tsuji W; Teramukai S; Ueno M; Toi M; Inamoto T
Breast Cancer; 2014 Jan; 21(1):86-95. PubMed ID: 22477265
[TBL] [Abstract][Full Text] [Related]
35. Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during 1977-2001.
Andersson M; Jensen MB; Engholm G; Henrik Storm H
Acta Oncol; 2008; 47(4):755-64. PubMed ID: 18465345
[TBL] [Abstract][Full Text] [Related]
36. Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women.
Biglia N; Peano E; Sgandurra P; Moggio G; Pecchio S; Maggiorotto F; Sismondi P
Gynecol Endocrinol; 2013 Mar; 29(3):263-7. PubMed ID: 23174088
[TBL] [Abstract][Full Text] [Related]
37. Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database.
Cronin-Fenton D; Lash TL; Ahern TP; Damkier P; Christiansen P; Ejlertsen B; Sørensen HT
Acta Oncol; 2018 Jan; 57(1):120-128. PubMed ID: 29202630
[TBL] [Abstract][Full Text] [Related]
38. The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy.
Zaky SS; Lund M; May KA; Godette KD; Beitler JJ; Holmes LR; O'Regan RM; Yu ES; Yu DS; Landry JC
Ann Surg Oncol; 2011 Oct; 18(10):2858-65. PubMed ID: 21442346
[TBL] [Abstract][Full Text] [Related]
39. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
[TBL] [Abstract][Full Text] [Related]
40. Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer.
Torrisi R; Bagnardi V; Rotmensz N; Scarano E; Iorfida M; Veronesi P; Luini A; Viale G; Santoro A; Colleoni M; Goldhirsch A
Breast Cancer Res Treat; 2011 Apr; 126(2):431-41. PubMed ID: 21221766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
